| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_03582f1d29959412ac150c22017fc284
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3388e28016dd42d77265cf7920775535
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cfc01f9093a10420d0ffe07449b25fb5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f3f0c32c723d89c529785cb26e7e6709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ccece6438449af3100180230819cea16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d708f836bb22f97ce8d5fffb26f004c3 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y301-06004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-465
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46 |
| filingDate |
2018-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fba5973df38594d67bf520f74daa6358
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7cff4a435a9992253413ec122af045e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ff323bb2b0970e79438b26d214439f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a020b5105ba4c5a64a85cacb17c65c3c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2ca895b268aa52a9f044a6defa6a9e7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24afe84b79b95f69bbd60444fd028252 |
| publicationDate |
2019-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019224283-A1 |
| titleOfInvention |
Method of treating mucopolysaccharidosis type iva |
| abstract |
Disclosed are methods and compositions for determining immunodominant peptides of target enzymes used in enzyme replacement therapy for lysosomal storage disorders. More specifically disclosed are immunodominant peptides for N-acetylgalactosamine-6-sulfatase (GALNS). Also disclosed are methods of inducing oral tolerance towards a target enzyme through oral administration of immunodominant peptides prior to commencing enzyme replacement therapy. More specifically disclosed is a method of inducing oral tolerance for GALNS, by orally administering specific immunodominant peptides for GALNS; in subjects suffering from mucopolysaccharidosis type IVA prior to commencing enzyme replacement therapy using GALNS. |
| priorityDate |
2018-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |